AzTrials
AzTrials

Terminal IllnessNCT00686673

Effect of a Decision Aid on Decision Making for Family Member's Disclosure of Terminal Illness

A study testing Providing tailored message on disclosing terminal illness in people with Terminal Illness, run by National Cancer Center, Korea at 14 sites in South Korea.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study is a randomized controlled trial that will compare two arms: an experimental intervention group that receives a decision aid consisting of an educational video and targeted manual providing a protocol for the family members' disclosing terminal illness to the patients and aimed at improving communication… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Terminal Illness
What is being tested?
Providing tailored message on disclosing terminal illness
Could I receive a placebo?
No, everyone receives an active treatment
How many people
440 participants
Where
14 sitesSouth Korea
Study dates
Jun 2008to Mar 2009
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient:
  • age≥ 18years
  • cancer patient
  • terminally ill
  • mentally competent
  • Family members:
Show all 10Show fewer
  • age≥ 18years
  • having terminally ill cancer patients
  • Spouse, daughter or son, parent, brother or sister
  • having ability to understand the content of educational material

Who cannot join

  • serious comorbidity(stroke, heart attack, acute or chronic respiratory, acute or chronic renal disease, or cancer)
  • inability to speak, hear or read Korean
  • mentally incompetence (schizophrenia, bipolar, psychiatric or addictive disorder, or severe emotional distress)
  • Pregnancy

Trial locations and contacts

14 sites in 1 country.

14 sites in 1 country

South Korea14 sites
  • National Cancer Center

    809 Madu-dong, Ilsan-gu, Goyang-si, Gyeonggi-do, 411-769

  • Bobath Memorial Hospital

    Bundang-gu, Seongnam-si,Gyeonggi-do, 463-805

  • Gyeongsang National University Hospital

    Chiram-dong, Jinju-si, Gyeongsangnam-do, 660-702

  • The Catholic University of Korea, Daejeon St. Mary's Hospital

    Daeheung-dong, Jung-gu, Daejeon, 301-804

  • Daegu Fatima Hospital

    Dong-gu, Daegu, 701-600

  • Korea University Guro Hospital

    Guro-gu, Seoul,, 152-703

  • Keimyung University Dongsan Medical Center

    Jung-gu, Daegu,, 700-712

  • Chungnam National University Hospital

    Jung-gu,Daejeon, 301-721

  • Kwangju Christian Hospital

    Kwangju, 503-715

  • Sunlin Hospital Handong University

    Pohang, 791-704

  • Gangneung Asan Hospital

    Sacheon-myeon, Gangneung-si, Gangwon-do, 210-711

  • Seoul National University Hospital

    Seoul, Seoul, 110-744

  • Kyung Hee University Medical Center

    Seoul, Seoul, 130-702

  • The Catholic University of Korea Kangnam St. Mary's Hospital

    Seoul, Seoul, 137-701

Other trials in South Korea

About this study

Official title: Effect of a Decision Aid on Decision Making for Family Member's Disclosure of Terminal Illness to Patient With Terminal Cancer

This study is a randomized controlled trial that will compare two arms: an experimental intervention group that receives a decision aid consisting of an educational video and targeted manual providing a protocol for the family members' disclosing terminal illness to the patients and aimed at improving communication, satisfaction with decision making process, and quality of life between patients and their family versus an attention control group that receives a video and non-tailored manual on pain control.

Read the detailed description

Inclusion and exclusion criteria:

This study is aimed at decreasing the decisional conflict among family members who are ready or not to disclose patients' terminal illness. The decision aid will lead to effective communication between patients and family and the effective decision making process will lead to the final outcome to improve the quality of life in patients and their family. This trial is limited to situations where the family and their patients are cognitively capable of participating in decision-making process.

Measures:

Baseline Measures. At baseline, before randomization, self-reported questionnaire is used to collect data. To correct possible confounders in this study, family' background variables are assessed on entry to the study, including sociodemographic and decisional conflicts, decisional-role preference, stage of readiness, level of anxiety and depression, and QOL.

Family decisional conflict is assessed using four subscales of the Decisional Conflict Scale which assessed how well informed participants feel about their choices and the associated benefits and risks; the clarity of their values; the support they have in the decision-making process; and their level of uncertainty. It consists of 16 items followed by a Likert response of 1, strongly agree, to 5, strongly disagree. A mean score is obtained for each participant. The Decisional Conflict Scale (DCS) is translated into Korean by two bilingual individuals, using a forward-backward translation procedure, and completed pilot test.

Family preference for role in decision making is assessed using a scale modeled on an instrument developed by Degner et al. We make family/patient dimension from modifying Degner and Sloan's second Control Preference Scale set, family/physician dimension. The options of modified set of five cards (family/patient dimension) range from the family making the decision mainly, through a collaborative model where the family and patient jointly decided, to a scenario where the patient made decision mainly. Family is asked to indicate whether they preferred an independent role (i.e., "that the family makes the final decision regarding which treatment the patient will receive or after considering patient's opinion"), shared role (i.e., "that the family and patient together select which treatment is best for the patient"), or a dependent role (i.e., "that the patient alone makes all the decisions regarding the patient's treatment or considers the family's opinion"). Family participant chose the decision-role statement that best described his/her preferred role in decision making. The Control Preference Scale (CPS) is translated into Korean by two bilingual individuals, using a forward-backward translation procedure, and completed pilot test.

Levels of family anxiety and depression is assessed by the Hospital Anxiety and Depression Scale which consists of 14 items, seven on anxiety and seven on depression, forming two sub-scales. Each item has four descriptive response options to be scored on a 0 to 3 scale. A value of 0 corresponds to not having the symptom, 3 corresponds to having the symptom to a high level. Scores for each of the two sub-scales are constructed by simple summation of its seven items. The developers have suggested that sub-scale scores of 0-7 represent non-cases, 8-10 represent doubtful cases, and 11-21 represent definite cases.

The Baseline Patient's Generic QOL:. Because we expect the effect of intervention for family to accompany change of patients' outcome, we measure patients' QOL and quality cancer care at baseline to observe secondary outcome related with effect of the decision aid.

Patient's QOL is assessed with QCQ-EOL. To correct possible confounders in this study, patient' background variables are obtained on entry to the study including sociodemographic and medical records.

Outcome Measures:

The primary outcome to be considered is the potential efficacy of this aid including family's decisional conflicts, satisfaction with decision making, and decisional-role preference, decisional regret, and physician and family acceptance of the decision aid.

Family satisfaction with decision making is assessed using the effective decision-making subscale of the decisional conflict instrument [O'Connor AM. Validation of a decisional conflict scale. Med Decis Making. 1995 Jan-Mar;15(1):25-30]. The subscale was four items regarding satisfaction with decision making (being informed, reflection of participant's own values, likelihood to comply, and satisfied). Scores for family satisfaction are reversed so that the higher scores reflect higher level of satisfaction (ie, a reversed Likert scale in which 5 is the highest scored). A mean score is obtained for each patient.

Physician and participant's acceptance of the decision aid is addressed using two questionnaires followed by a Likert response of 1, strongly agree, to 5, strongly disagree (i.e., family assessment item, "The decision support was useful to me in reaching a decision", "I would recommend that others facing the decision use the support", "The decision support interfered with my relationship with patient", Physician assessment item, "I feel the family has made an informed choice", "The decision support was useful in helping this family understand the risk and benefits of the disclosure on terminal illness", "The decision support did not interfere with my anticipated physician-patient relationship with my patient")[Brundage et al2001]. Decision regret is measured by the Decision Regret Scale which is useful tool for measuring regret after decisions at a particular point in time developed by O'Connor et al. It consists of 5 items followed by a Likert response of 1, strongly agree, to 5, strongly disagree. The definition of decision regret is remorse or distress over a decision[O'Connor]. These items were whether regret was felt to be present, whether the decision was the right one for him/her, whether he/she would make same decision again in the same circumstances, whether the decision was a wise one, and whether the decision had resulted in harm. The Decision Regret Scale is translated into Korean by two bilingual individuals, using a forward-backward translation procedure, and completed pilot test.

Secondary outcomes include the levels of family anxiety and depression,and family's QOL.

Levels of family anxiety and depression is assessed with the Hospital Anxiety Depression Scale. The actual disclosure following use of the material is assessed by following items including chosen disclosure and if terminal illness disclosed "who, and when disclose patients' terminal condition" and it is assessed at 1, 3, and 6 months after sending the material. Levels of family anxiety and depression, family decision regret, family preference for role in decision making, and patient's QOL are assessed at 1, 3, and 6 months after sending the video.

Being tested
Providing tailored message on disclosing terminal illness, Providing non-tailored message on pain control
Keywords
DECISION AIDS

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Providing tailored message on disclosing terminal illnessBehavioural

    an experimental intervention group that receives a decision aid consisting of targeted educational video and manual providing a protocol for disclosing terminal illness and aimed at improving communication between patients and their family

  • Providing non-tailored message on pain controlBehavioural

    an attention control group that receives non-tailored video and manual on pain control

Study groups in NCT00686673
Study groupRoleWhat they receive
AExperimentalProviding Videotape-based material \& tailored workbook to make informed choice of disclosing terminal illness to patients
Receives: Behavioral: Providing tailored message on disclosing terminal illness
BOtherAttention control arm: Providing videotape-based material \& non-tailored workbook about pain control
Receives: Behavioral: Providing non-tailored message on pain control

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Decisional conflict & satisfaction: Decisional Conflict Scale

    Measured: baseline, 1month, 3month, 6month

Secondary outcomes (1)
  1. Quality of Life: Quality Care Questionnaire-End of Life(QCQ-EOL), Korean version of the Caregiver Quality of Life Index - Cancer(CQOLC-K)

    Measured: baseline, 1month, 3month, 6month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 May 2008 (estimated)
  2. Study startJun 2008
  3. Primary completionJun 2008
  4. Study completionMar 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
440 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00686673
Sponsor's protocol ID
nccncs-08-142
Status last verified
Mar 2009
First submitted
28 May 2008
Last updated
15 Feb 2011
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing Providing tailored message on disclosing terminal illness in people with Terminal Illness, run by National Cancer Center, Korea at 14 sites in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Feb 2011. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 14 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Decisional conflict & satisfaction: Decisional Conflict Scale (time frame: baseline, 1month, 3month, 6month). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2011.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in